Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 5:13 AM ET

Biotechnology

Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

123 Employees

Phone:

415-365-5600

Fax:

415-365-5601

Key Executives for Five Prime Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Age: 66
Total Annual Compensation: $525.0K
Chief Medical Officer and Executive Vice President
Age: 57
Total Annual Compensation: $382.1K
Chief Business Officer, Executive Vice President and Director
Age: 46
Total Annual Compensation: $364.0K
Compensation as of Fiscal Year 2014.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics Announces Key Executive Appointments

Five Prime Therapeutics, Inc. announced the appointment of Kevin Baker, Ph.D., as Senior Vice President Development Sciences, to oversee pharmacology, toxicology, bio-analytics, process development, manufacturing and project management. In addition, Robert Sikorski, M.D., Ph.D., was promoted to Senior Vice President of Global Clinical Development where he will oversee all clinical development, pharmacovigilance and pharmacokinetics, and will play a strategic role in advancing Five Prime's immuno-oncology portfolio. Dr. Baker joins Five Prime from Audentes Therapeutics, where he was Senior Vice President, Preclinical Development. Prior to joining Five Prime as Vice President of Global Clinical Development in 2014, Dr. Sikorski was Senior Director, Global Oncology Research and Development at MedImmune (the Biologics Division of AstraZeneca, PLC), where he and his team led the clinical development of a portfolio of immuno-oncology drugs.

Five Prime Therapeutics, Inc. Announces Preliminary Data from the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers Symposium

Five Prime Therapeutics, Inc. announced preliminary data from Part 1 of the ongoing Phase 1 clinical trial of FPA144 in patients with solid tumors, including gastric cancer, at a poster presentation at the American Society of Clinical Oncology’s (ASCO) 2016 Gastrointestinal Cancers Symposium in San Francisco. FPA144 Phase 1 Safety and Pharmacokinetic Summary: Safety data from 27 patients and pharmacokinetic (PK) data from 23 patients from Part 1a (3+3 dose escalation in solid tumor patients) and Part 1b (parallel escalating doses in gastric cancer patients); FPA144 was well tolerated in patients with advanced solid tumors up to 15 mg/kg; No dose-limiting toxicities (DLTs) were observed and a maximum-tolerated dose (MTD) was not reached in Part 1; The most common treatment-emergent adverse events were Grades 1 or 2 and self-limiting; The safety profile appears differentiated from small molecule kinase inhibitors targeting FGF receptors; for example, no treatment-related hyperphosphatemia was observed; The most common treatment-related adverse events were: fatigue (25.9%), nausea (11.1%), diarrhea (7.4%), dizziness (7.4%)and dry eye (7.4%); PK characteristics support once every other week or less frequent dosing. Preliminary Data on Anti-tumor Activity: Anti-tumor activity in patients with gastric cancer whose tumors overexpress the FGFR2b protein (the initial target patient population for FPA144): First radiographic assessment by RECIST 1.1 of anti-tumor activity in six patients with FGFR2b-positive gastric cancer in Part 1b; 2 Partial Responses (1 confirmed who received 6 mg/kg, 1 unconfirmed who received 10 mg/kg); 3 Stable Disease (2 confirmed who received 3 mg/kg and 10 mg/kg, respectively; 1 unconfirmed who received 10 mg/kg); 1 Progressive Disease (who received 10 mg/kg); Patients were classified 3+ by an IHC molecular diagnostic test. Anti-tumor activity in a patient with urothelial bladder cancer: A confirmed Partial Response by CT (RECIST 1.1) and metabolic response by PET was observed in a urothelial bladder cancer patient who received 3 mg/kg from Part 1a; The patient’s tumor was classified 2+ by an IHC molecular diagnostic test, suggesting that FPA144 may be active in tumors with moderate levels of FGFR2b protein overexpression; Encourages investigation of the potential for FPA144 therapy in tumor types other than gastric cancer. All patients who showed anti-tumor activity received doses below the 15 mg/kg dose being assessed in Part 2 of the trial.

Five Prime Therapeutics, Inc. Announces the Resignation of Julie Hambleton as Executive Vice President and Chief Medical Officer and an Employee of the Company, Effective as of February 15, 2016

On January 18, 2016, Julie Hambleton notified Five Prime Therapeutics, Inc. that she will resign as Executive Vice President and Chief Medical Officer and an employee of the Company, effective as of February 15, 2016, in order to pursue other interests.

Similar Private Companies By Industry

Company Name Region
Lifeline Technologies, Inc. United States
Lypro Biosciences, Inc. United States
CytoGenix, Inc. United States
allvivo, Inc. United States
Bioarray Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.